Roseann Benanti, NP
Primary Care · Englewood, NJNPI 1780330902
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $15,525 of the $24,297 with a category attached, or 63.9%. Madrigal Pharmaceuticals accounts for 78.8% of it on its own, with 28 other manufacturers making up the rest. 2025 is the largest year on record at $20,675, more than ten times the $791 reported in 2022. Among primary care clinicians in NJ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 332 payments — averaging $73.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Madrigal Pharmaceuticals$19K
- Johnson & Johnson$786
- AbbVie$764
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$538
- Janssen Scientific Affairs, LLC$444
- Intercept Pharmaceuticals, Inc.$380
- plus $2K from 23 others
What the payments were for
- Speaking & faculty fees$15,52564%
- Travel & lodging$1,1865%
- Food & beverage$7,39130%
- Education$1951%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Madrigal Pharmaceuticals | 69 | $19,144 |
| Johnson & Johnson | 27 | $786 |
| AbbVie | 58 | $764 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 41 | $538 |
| Janssen Scientific Affairs, LLC | 5 | $444 |
| Intercept Pharmaceuticals, Inc. | 18 | $380 |
| Bristol Myers Squibb | 26 | $301 |
| Ironwood Pharmaceuticals, Inc | 4 | $292 |
| Sanofi | 2 | $242 |
| Pfizer | 11 | $181 |
| Daiichi Sankyo Inc. | 10 | $158 |
| Takeda Pharmaceuticals U.S.A., Inc. | 9 | $158 |
| Lilly USA, LLC | 7 | $124 |
| Celltrion USA Inc. | 7 | $111 |
| Phathom Pharmaceuticals, Inc. | 9 | $111 |
| Aimmune Therapeutics, Inc. | 6 | $109 |
| E.r. Squibb & Sons, L.L.C. | 1 | $104 |
| Ardelyx, Inc. | 3 | $48 |
| Organon | 3 | $48 |
| Braintree Laboratories, Inc. | 3 | $46 |
| Nestle Healthcare Nutrition Inc. | 3 | $40 |
| Ipsen Biopharmaceuticals, Inc | 2 | $38 |
| Ferring Pharmaceuticals Inc. | 2 | $30 |
| QOL Medical, LLC | 1 | $22 |
| Biocon Biologics Inc | 1 | $21 |
| Boston Scientific | 1 | $18 |
| Novo Nordisk | 1 | $16 |
| Fresenius Kabi USA, LLC | 1 | $13 |
| Regeneron Healthcare Solutions, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$24,297 in reported general payments places this provider in the 95th percentile of 330 primary care providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ZenpepLipase/Protease/Amylase | 12 | $31,264 |
| Pantoprazole Sodium | 83 | $1,161 |
| Vancomycin Hcl | 12 | $1,049 |
| Sucralfate | 13 | $742 |
| Omeprazole | 36 | $619 |
| Famotidine | 47 | $561 |
| Atorvastatin Calcium | 36 | $407 |
| Dicyclomine Hcl | 28 | $315 |
| Hydrocortisone | 25 | $223 |
| Esomeprazole Magnesium | 17 | $202 |
| Ondansetron Hcl | 26 | $193 |
| Alprazolam | 21 | $148 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 16 | $118 |
| Azithromycin | 17 | $91 |
| Ciprofloxacin Hcl | 14 | $88 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Aimmune Therapeutics, Inc.Zenpep | $109 | $31,26412 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 330 primary care providers in New Jersey.
Other primary care in Englewood
- Marcelo MarinEnglewood$17K
- Michael Zito GovertNeptune$61K
- Jennifer EdwardsPrinceton$14K
- Mary Grace TolentinoJersey City$9K
- Kevin Robert ReyladoNorth Arlington$8K
- Carlo SebelloJersey City$8K
- Karam WehbehPaterson$7K
- Shazam BacchusNewark$7K
- Anna NievesBasking Ridge$7K
- Kristen BeerFreehold$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.